공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 감염증 분자진단 시장 : 증후군, 플렉스, 장소, 국가별 : COVID-19의 영향 예측/분석, 경영 가이드 및 커스터마이제이션(2021-2025년)

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021 - 2025

리서치사 Howe Sound Research
발행일 2021년 09월 상품 코드 1028752
페이지 정보 영문 21 Pages
가격
US $ 6,995 ₩ 8,376,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,567,000 PDF (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,759,000 PDF (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 감염증 분자진단 시장 : 증후군, 플렉스, 장소, 국가별 : COVID-19의 영향 예측/분석, 경영 가이드 및 커스터마이제이션(2021-2025년) Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021 - 2025
발행일 : 2021년 09월 페이지 정보 : 영문 21 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

임상 진단 업계에서의 감염증 분자진단 시장은 기록적인 성장을 이루려 하고 있습니다. 감염 검사는 생명공학, 특히 유전체학의 폭발적인 발전으로 직접 혜택을 받고 있습니다.

세계의 감염증 분자진단(Molecular Diagnostics for Infectious Disease) 시장을 조사했으며, 시장 개요와 더불어 증후군, 플렉스, 장소, 국가별 동향 및 시장 진출기업 프로필 등을 제공합니다.

목차

제1장 시장 가이드

  • 전략 상황 분석 및 COVID-19의 영향
  • 임원, 마케팅, 영업, 사업 개발 직원 안내
  • 경영 컨설턴트와 투자 자문 안내

제2장 서론과 시장 정의

  • 분자 진단이란 무엇인가
  • 진단 혁명
  • 시장 정의
    • 수익
  • 조사 방법
    • 저자
    • 소스
  • 전망 : 건강 관리, IVD 산업 및 COVID-19 유행
    • 세계의 보건 지출
    • 진단 지출
    • 진단을 위한 보험의 중요 역할

제3장 감염-질환별 시장 분석

  • HIV-인간 면역 결핍 바이러스(AIDS)
    • 바이러스학
    • 진단
    • 검사
    • 시장 기회 분석
  • HBV-B형 간염
    • 바이러스학
    • 기전
    • 진단
    • 시장 기회 분석
  • HCV-C형 간염
    • 분류
    • 구조
    • 분자 생물학
    • 복제
    • 유전자형
    • 시장 기회 분석
  • HPV-인유두종 바이러스
    • 바이러스학
    • 진단
    • 시장 기회 분석
  • 독감
    • 바이러스학
    • 검사
    • 시장 기회 분석
  • CTGC-클라미디아/임질
    • 임질
    • 클라미디아
    • 검사
    • 시장 기회 분석
  • 결핵
    • 마이코 박테리아
    • 진단
    • 역학
    • 분자 진단 검사
    • 시장 기회 분석
  • MRSA-메티실린 내성 황색 포도상 구균
    • 진단
    • FDA 승인 분자 검사
    • 시장 기회 분석
  • VRE-반코마이신 내성 장구균
    • FDA 승인 VRE를 위한 분자 진단 검사
    • 시장 기회 분석
  • 혈액 검사
    • 채혈 및 검사
    • FDA 승인 멀티 플렉스 분석
    • 시장 기회 분석
  • COVID-19
    • 징후와 증상
    • 감염
    • 진단
    • 예방
    • 관리
    • 예후
  • 유행 진단
    • 위험 관리-스파크 앤 스프레드
    • 진단 기술-핵산 기반
    • 진단 기술-면역 측정법 및 혈청학
    • 출시까지의 시간과 준비 문제
    • 유행 관리 멀티 플렉스, 인식되지 않은 역할

제4장 산업 개요

  • 역동적인 시장 플레이어
    • 학술 연구소
    • 진단 검사 개발자
    • 계측 공급 업체
    • 유통 및 시약 공급 업체
    • 독립 시험 연구소
    • 공적 국립/지역 연구소
    • 병원 검사실
    • 실천을 위한 검사실
    • 감사 기관
    • 인증 기관
  • 임상 검사 시장 부문
    • 기존 시장 세분화
    • 실험실 초점 및 세분화
  • 산업 구조
    • 병원 검사 점유율
    • 규모 경제
    • 실천을 위한 검사실
    • 의사와 POCT

제5장 주요 기업 프로필

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • bioM? rieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid(now Danaher)
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis NV/Curetis GmbH
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin SpA
  • Eiken Chemical
  • Enzo Life Sciences, Inc
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics
  • Genedrive
  • Genetic Signatures
  • GenMark Dx
  • Grifols
  • Hibergene Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Luminex Corp
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech
  • Millipore Sigma
  • Mindray
  • Mobidiag
  • Nanomix
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Primerdesign
  • Prominex
  • Qiagen Gmbh
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher Scientific Inc
  • Veramarx
  • Veredus Laboratories
  • Vir
  • XCR Diagnostics

제6장 시장 동향

  • 성장 촉진 요인
    • 새로운 시장을 만들어내는 새로운 유전자형
    • 인구 고령화는 모든 진단에 보탬이 되다
    • 개발 도상국이 이끄는 감염증 분자진단 성장
    • 포인트 오브 케어-중앙 집중식이 기세를 잃고 있는 이유
    • 자기 검사
    • 속도 필요성
    • COVID 유행
  • 성장 억제 요인
    • 저비용
    • 감염 감소
    • 건강 피해
    • 경제 성장이 삶의 질 향상
  • 계측 및 자동화
    • 시장 점유율 핵심 장비
    • 수축 기계
    • 멀티플렉스 포인트 오브 케어 및 속도 계수
  • 진단 기술 개발
    • 패혈증 검사 시장-새로운 방향성
    • 파괴력 POCT/자기 검사
    • 유전학-알려진 모든 감염에 대응하는 하나의 검사
    • 항생제 내성 유전자-진단 간소화

제7장 감염증 분자 진단-신 개발

제8장 분자 진단 감염 세계 시장

  • 국가별 세계 시장 개요
    • 표-국가별 세계 시장
    • 차트-국가별 세계 시장
  • 세계의 시장-증후군별-개요
    • 표-세계의 시장-증후군별
    • 차트-세계의 시장-증후군별-기준/마지막 학기의 비교
    • 차트-세계의 시장-증후군별-기준년도
    • 차트-세계의 시장-증후군별-연말
    • 차트-세계의 시장-증후군별-연도별 점유율
    • 차트-세계의 시장-증후군별-부문 성장
  • 세계의 시장-플렉스별-개요
    • 표-세계의 시장-플렉스별
    • 차트-세계의 시장-플렉스별-기준/마지막 학기의 비교
    • 차트-세계의 시장-플렉스별-기준년도
    • 차트-세계의 시장-플렉스별-연말
    • 차트-세계의 시장-플렉스별-연도별 점유율
    • 차트-세계의 시장-플렉스별-부문 성장
  • 세계의 시장-위치별-개요
    • 표-세계의 시장-위치별
    • 차트-세계의 시장-위치별-기준/마지막 학기의 비교
    • 차트-세계의 시장-위치별-기준년도
    • 차트-세계의 시장-위치별-연말
    • 차트-세계의 시장-위치별-연도별 점유율
    • 차트-세계의 시장-위치별-부문 성장

제9장 세계의 감염증 분자진단 시장-증후군별

  • 호흡기
  • 위장
  • 수막염/뇌염
  • 성병
  • 기타

제10장 세계의 감염증 분자진단 시장-플렉스별

  • 싱글 플렉스
  • 이중
  • 삼중
  • 멀티 플렉스 기술

제11장 세계의 감염증 분자진단 시장-위치별

  • 병원 검사실
  • 외래 검사실
  • POC
  • 기타

제12장 부록

NJH 21.10.12

Table of Tables

  • Table 1 Classification of HIV Species
  • Table 2 HIV Tests - CMS Codes & Prices
  • Table 3 Current HIV Molecular Tests and Instruments Used
  • Table 4 HBV Tests - CMS Codes & Prices
  • Table 5 HCV Tests - CMS Codes & Prices
  • Table 6 HPV Clearance Rates
  • Table 7 HPV Tests - CMS Codes & Prices
  • Table 8 HPV Tests, Technology, Types
  • Table 9 Types of Influenza Tests
  • Table 10 Influenza Tests - CMS Codes & Prices
  • Table 11 FDA Cleared Molecular Assays for Influenza
  • Table 12 FDA Cleared NAAT CTGC Tests
  • Table 13 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 14 CTGC Tests - CMS Codes & Prices
  • Table 15 FDA Approved MDx Tests for Tuberculosis
  • Table 16 Tuberculosis Tests - CMS Codes & Prices
  • Table 17 FDA Approved Tests for MRSA
  • Table 18 MRSA Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for VRE
  • Table 20 VRE Tests - CMS Codes & Prices
  • Table 21 FDA Approved Multiplex Assays
  • Table 22 Characteristics of Coronavirus Pandemic Infections
  • Table 23 COVID-19 Symptoms
  • Table 24 Market Players by Type
  • Table 25 Clinical Laboratory Departments and Segments
  • Table 26 Laboratory Management Focus - Different Approaches
  • Table 27 Key Segmentation Variables Going Forward
  • Table 28 Five Factors Driving Growth
  • Table 29 Four Factors Limiting Growth
  • Table 30 Key Diagnostic Laboratory Technology Trends
  • Table 31 - Global Market by Region
  • Table 32 Global Market by Syndrome
  • Table 33 Global Market by Plex
  • Table 34 Global Market by Place
  • Table 35 Respiratory by Country
  • Table 36 Gastrointestinal by Country
  • Table 37 Blood by Country
  • Table 38 Meningitis/Encephalitis by Country
  • Table 39 Sexually Transmitted Disease by Country
  • Table 40 Other by Country
  • Table 41 Single Plex by Country
  • Table 42 Duplex by Country
  • Table 43 Triplex by Country
  • Table 44 Multiplex by Country
  • Table 45 Hospital Lab by Country
  • Table 46 Outpatient Lab by Country
  • Table 47 POC by Country
  • Table 48 Other Place by Country
  • Table 49 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Map - Global Healthcare Spending Per Capita
  • Figure 2 The Lab Test Pie - Wholesale and Retail
  • Figure 3 HIV Virion
  • Figure 4 Diagram of the HIV Replication Cycle
  • Figure 5 The Structure of the HBV Virus
  • Figure 6 Hepatitis B Replication
  • Figure 7 Structure of the HCV Virus
  • Figure 8 HCV Replication Cycle
  • Figure 9 Structure of the Influenza Virion
  • Figure 10 Influenza Replication
  • Figure 11 Scanning Electronmicrograph of Tuberculosis
  • Figure 12 Percentage of World Population Over 65
  • Figure 13 Chart Infectious Disease Decline
  • Figure 14 Global Market Shares Chart
  • Figure 15 Global Market by Syndrome - Base vs. Final
  • Figure 16 Global Market by Syndrome Base Year
  • Figure 17 Global Market by Syndrome End Year
  • Figure 18 Syndrome Share by Year
  • Figure 19 Syndrome Segments Growth
  • Figure 20 Global Market by Plex - Base vs. Final
  • Figure 21 Global Market by Plex Base Year
  • Figure 22 Global Market by Plex End Year
  • Figure 23 Plex Share by Year
  • Figure 24 Plex Segments Growth
  • Figure 25 Global Market by Place - Base vs. Final
  • Figure 26 Global Market by Place Base Year
  • Figure 27 Global Market by Place End Year
  • Figure 28 Place Share by Year
  • Figure 29 Place Segments Growth
  • Figure 30 Respiratory Growth
  • Figure 31 Gastrointestinal Diagnostics Growth
  • Figure 32 Blood Growth
  • Figure 33 Meningitis/Encephalitis Growth
  • Figure 34 Sexually Transmitted Disease Growth
  • Figure 35 Other Growth
  • Figure 36 Single Plex Growth
  • Figure 37 Duplex Growth
  • Figure 38 Triplex Growth
  • Figure 39 Multiplex Growth
  • Figure 40 Hospital Lab Growth
  • Figure 41 Outpatient Lab Growth
  • Figure 42 POC Growth
  • Figure 43 Other Place Growth

OVERVIEW:

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like:

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Strategic Situation Analysis and Impact of COVID-19
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What are Molecular Diagnostics?
  • 2.2 The Diagnostics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenues
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Market Analysis by Disease

  • 3.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.1.1 Virology
      • 3.1.1.1 Classification
      • 3.1.1.2 Structure and genome
      • 3.1.1.3 Tropism
      • 3.1.1.4 Replication cycle
      • 3.1.1.5 Genetic variability
    • 3.1.2 Diagnosis
    • 3.1.3 Testing
      • 3.1.3.1 Antibody tests
      • 3.1.3.2 Point of Care Tests (POCT)
      • 3.1.3.3 Antigen Tests
      • 3.1.3.4 Nucleic acid-based tests (NAT)
      • 3.1.3.5 Other tests used in HIV treatment
    • 3.1.4 Market Opportunity Analysis
  • 3.2 HBV - Hepatitis B
    • 3.2.1 Virology
      • 3.2.1.1 Genome
      • 3.2.1.2 Pathogenesis
      • 3.2.1.3 Hepatitis B virus replication
      • 3.2.1.4 Serotypes and genotypes
    • 3.2.2 Mechanisms
    • 3.2.3 Diagnosis
    • 3.2.4 Market Opportunity Analysis
  • 3.3 HCV - Hepatitis C
    • 3.3.1 Taxonomy
    • 3.3.2 Structure
      • 3.3.2.1 Genome
    • 3.3.3 Molecular biology
    • 3.3.4 Replication
    • 3.3.5 Genotypes
      • 3.3.5.1 Clinical importance
    • 3.3.6 Market Opportunity Analysis
  • 3.4 HPV - Human papillomavirus
    • 3.4.1 Virology
      • 3.4.1.1 E6/E7 proteins
      • 3.4.1.2 Role in cancer
      • 3.4.1.3 E2 research
      • 3.4.1.4 Latency period
      • 3.4.1.5 Clearance
    • 3.4.2 Diagnosis
      • 3.4.2.1 Cervical testing
      • 3.4.2.2 Oral testing
      • 3.4.2.3 Testing men
      • 3.4.2.4 Other testing
    • 3.4.3 Market Opportunity Analysis
  • 3.5 Influenza
    • 3.5.1 Virology
      • 3.5.1.1 Types of virus
      • 3.5.1.2 Influenzavirus A
      • 3.5.1.3 Influenzavirus B
      • 3.5.1.4 Influenzavirus C
      • 3.5.1.5 Structure, properties, and subtype nomenclature
      • 3.5.1.6 Replication
    • 3.5.2 Testing
      • 3.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.5.3 Market Opportunity Analysis
  • 3.6 CTGC - Chlamydia/Gonorhea
    • 3.6.1 Gonorrhea
      • 3.6.1.1 Diagnosis
      • 3.6.1.2 Screening
    • 3.6.2 Chlamydia
      • 3.6.2.1 Diagnosis
      • 3.6.2.2 Screening
    • 3.6.3 Testing
      • 3.6.3.1 Nucleic acid amplification tests (NAATs)
      • 3.6.3.2 Performance of NAAT Tests
    • 3.6.4 Market Opportunity Analysis
  • 3.7 Tuberculosis
    • 3.7.1 Mycobacteria
    • 3.7.2 Diagnosis
      • 3.7.2.1 Active tuberculosis
      • 3.7.2.2 Latent tuberculosis
    • 3.7.3 Epidemiology
    • 3.7.4 Molecular Diagnostic Tests
    • 3.7.5 Market Opportunity Analysis
  • 3.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.8.1 Diagnosis
    • 3.8.2 FDA Approved Molecular Tests
    • 3.8.3 Market Opportunity Analysis
  • 3.9 VRE - Vancomycin-resistant Enterococcus
    • 3.9.1 FDA Approved MDx Tests for VRE
    • 3.9.2 Market Opportunity Analysis
  • 3.10 Blood Screening
    • 3.10.1 Collection and Testing
    • 3.10.2 FDA Approved Multiplex Assays
    • 3.10.3 Market Opportunity Analysis
  • 3.11 COVID-19
    • 3.11.1 Signs and symptoms
    • 3.11.2 Transmission
    • 3.11.3 Diagnosis
    • 3.11.4 Prevention
    • 3.11.5 Management
    • 3.11.6 Prognosis
  • 3.12 Pandemic Diagnostics
    • 3.12.1 Risk Management - Spark and Spread
    • 3.12.2 Dx Technology - Nucleic Acid Based
    • 3.12.3 Dx Technology - Immunoassay & Serology
    • 3.12.4 Time to Market and Preparedness Issues
    • 3.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Distributor and Reagent Supplier
    • 4.1.5 Independent Testing Lab
    • 4.1.6 Public National/regional lab
    • 4.1.7 Hospital lab
    • 4.1.8 Physician Office Labs
    • 4.1.9 Audit Body
    • 4.1.10 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

  • 5.1 Abacus Diagnostica
  • 5.2 Abbott Diagnostics
  • 5.3 Accelerate Diagnostics
  • 5.4 Ador Diagnostics
  • 5.5 Akonni Biosystems
  • 5.6 Alveo Technologies
  • 5.7 Applied BioCode
  • 5.8 Aus Diagnostics
  • 5.9 Beckman Coulter Diagnostics
  • 5.10 Becton, Dickinson and Company
  • 5.11 Binx Health
  • 5.12 Biocartis
  • 5.13 bioMérieux Diagnostics
  • 5.14 Bio-Rad Laboratories, Inc
  • 5.15 Bosch Healthcare Solutions GmbH
  • 5.16 Cepheid (now Danaher)
  • 5.17 Chembio
  • 5.18 Co Diagnostics
  • 5.19 Credo Diagnostics Biomedical
  • 5.20 Cue Health
  • 5.21 Curetis N.V. / Curetis GmbH
  • 5.22 Diagenode Diagnostics
  • 5.23 Diascopic
  • 5.24 Diasorin S.p.A
  • 5.25 Eiken Chemical
  • 5.26 Enzo Life Sciences, Inc
  • 5.27 Eurofins Scientific
  • 5.28 Fluxergy
  • 5.29 Fulgent Genetics
  • 5.30 Fusion Genomics
  • 5.31 Genedrive
  • 5.32 Genetic Signatures
  • 5.33 GenMark Dx
  • 5.34 Grifols
  • 5.35 Hibergene Diagnostics
  • 5.36 Hologic
  • 5.37 Illumina
  • 5.38 Immunexpress
  • 5.39 Inflammatix
  • 5.40 Invetech
  • 5.41 Janssen Diagnostics
  • 5.42 Karius
  • 5.43 Lexagene
  • 5.44 LightDeck Diagnostics
  • 5.45 Luminex Corp
  • 5.46 Lumos Diagnostics
  • 5.47 Mammoth Biosciences
  • 5.48 Maxim Biomedical
  • 5.49 Meridian Bioscience
  • 5.50 Mesa Biotech
  • 5.51 Millipore Sigma
  • 5.52 Mindray
  • 5.53 Mobidiag
  • 5.54 Nanomix
  • 5.55 Operon
  • 5.56 Oxford Nanopore Technologies
  • 5.57 Panagene
  • 5.58 Perkin Elmer
  • 5.59 Primerdesign
  • 5.60 Prominex
  • 5.61 Qiagen Gmbh
  • 5.62 Quantumdx
  • 5.63 Quidel
  • 5.64 Roche Molecular Diagnostics
  • 5.65 Saw Diagnostics
  • 5.66 Seegene
  • 5.67 Siemens Healthineers
  • 5.68 Sona Nanotech
  • 5.69 SpeeDx
  • 5.70 T2 Biosystems
  • 5.71 Thermo Fisher Scientific Inc
  • 5.72 Veramarx
  • 5.73 Veredus Laboratories
  • 5.74 Vir
  • 5.75 XCR Diagnostics

6 Market Trends

  • 6.1 Factors Driving Growth
    • 6.1.1 New Genotypes Creating New Markets
    • 6.1.2 Aging Population a Boon for All Diagnostics
    • 6.1.3 Developing World Driving ID Dx Growth
    • 6.1.4 Point of Care - Why Centralization is Losing Steam
    • 6.1.5 Self Testing
    • 6.1.6 The Need for Speed
    • 6.1.7 The COVID Pandemic
  • 6.2 Factors Limiting Growth
    • 6.2.1 Lower Costs
    • 6.2.2 Infectious Disease is Declining
    • 6.2.3 Wellness Hurts
    • 6.2.4 Economic Growth improves Living Standards
  • 6.3 Instrumentation and Automation
    • 6.3.1 Instruments Key to Market Share
    • 6.3.2 The Shrinking Machine
    • 6.3.3 Multiplex, Point of Care and The Speed Factor
  • 6.4 Diagnostic Technology Development
    • 6.4.1 The Sepsis Testing Market - A New Direction?
    • 6.4.2 POCT/Self Testing as a Disruptive Force
    • 6.4.3 The Genetics Play - One Test for All Known Infections
    • 6.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

7 Molecular Dx - Infectious Disease Recent Developments

  • 7.1 Recent Developments - Importance and How to Use This Section
    • 7.1.1 Importance of These Developments
    • 7.1.2 How to Use This Section
  • 7.2 Home Test Company Prenetics to go Public
  • 7.3 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.4 Lucira Health Posts Revenue Growth on OTC C19 Test
  • 7.5 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.6 Talis Biomedical Discusses Point-of-Care
  • 7.7 Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.8 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.9 Hologic to Acquire Mobidiag
  • 7.10 Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.11 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.12 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.13 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.14 Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.15 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.16 Scanogen Developing 90 Minute Infection Test
  • 7.17 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.18 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.19 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.20 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.21 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.22 Lumos Diagnostics Closes $15M Series A Funding
  • 7.23 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
  • 7.24 New Genomic Tests Diagnose Deadly Infections Faster
  • 7.25 Biotia Raises $2.4M Seed Round
  • 7.26 STDs resurge in US
  • 7.27 Ares Genetics signs R&D agreement with leading global IVD corporation
  • 7.28 Cell-Free DNA Used for Infectious Disease Testing
  • 7.29 One BioMed Raises $5M

8 The Global Market for Molecular Diagnostics Infectious Disease

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Syndrome - Overview
    • 8.2.1 Table - Global Market by Syndrome
    • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Syndrome - Base Year
    • 8.2.4 Chart - Global Market by Syndrome - End Year
    • 8.2.5 Chart - Global Market by Syndrome - Share by Year
    • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 8.3 Global Market by Plex - Overview
    • 8.3.1 Table - Global Market by Plex
    • 8.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Plex - Base Year
    • 8.3.4 Chart - Global Market by Plex - End Year
    • 8.3.5 Chart - Global Market by Plex - Share by Year
    • 8.3.6 Chart - Global Market by Plex - Segments Growth
  • 8.4 Global Market by Place - Overview
    • 8.4.1 Table - Global Market by Place
    • 8.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Place - Base Year
    • 8.4.4 Chart - Global Market by Place - End Year
    • 8.4.5 Chart - Global Market by Place - Share by Year
    • 8.4.6 Chart - Global Market by Place - Segments Growth

9 Global MDx Infectious Disease Markets - By Syndrome

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Gastrointestinal
    • 9.2.1 Table Gastrointestinal - by Country
    • 9.2.2 Chart - Gastrointestinal Growth
  • 9.3 Blood
    • 9.3.1 Table Blood - by Country
    • 9.3.2 Chart - Blood Growth
  • 9.4 Meningitis/Encephalitis
    • 9.4.1 Table Meningitis/Encephalitis - by Country
    • 9.4.2 Chart - Meningitis/Encephalitis Growth
  • 9.5 Sexually Transmitted Disease
    • 9.5.1 Table Sexually Transmitted Disease - by Country
    • 9.5.2 Chart - Sexually Transmitted Disease Growth
  • 9.6 Other
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global MDx Markets for Infectious Disease - by Plex

  • 10.1 Single Plex
    • 10.1.1 Table Single Plex - by Country
    • 10.1.2 Chart - Single Plex Growth
  • 10.2 Duplex
    • 10.2.1 Table Duplex - by Country
    • 10.2.2 Chart - Duplex Growth
  • 10.3 Triplex
    • 10.3.1 Table Triplex - by Country
    • 10.3.2 Chart - Triplex Growth
  • 10.4 Multiplex Technology
    • 10.4.1 Table Multiplex - by Country
    • 10.4.2 Chart - Multiplex Growth

11 Global MDx Infectious Disease Markets - by Place

  • 11.1 Hospital Lab
    • 11.1.1 Table Hospital Lab - by Country
    • 11.1.2 Chart - Hospital Lab Growth
  • 11.2 Outpatient Lab
    • 11.2.1 Table Outpatient Lab - by Country
    • 11.2.2 Chart - Outpatient Lab Growth
  • 11.3 POC
    • 11.3.1 Table POC - by Country
    • 11.3.2 Chart - POC Growth
  • 11.4 Other Place
    • 11.4.1 Table Other Place- by Country
    • 11.4.2 Chart - Other Place Growth

12 Appendices

  • 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule
Back to Top
전화 문의
F A Q